Publikasi Scopus FKUI 2021 per tanggal 30 Juni 2021 (428 artikel)

Hariyanto N.I., Purwandhita R.P., Syahrani R.A., Louisa M., Wanandi S.I.
57222706851;57202377042;57204103147;41461551400;36099320700;
Role of TGF-β1 in human breast cancer stem cells
2021
JPMA. The Journal of the Pakistan Medical Association
71 2)
2
S84
S89
Master Program in BioMedical Sciences, Indonesian Medical Education and Research Institute (IMERI)Jakarta, Indonesia; Department of Molecular Biology and Proteomics, Indonesian Medical Education and Research Institute (IMERI)Jakarta, Indonesia; Department of Pharmacology, Universitas IndonesiaJakarta, Indonesia; Department of BioChemistry and Molecular Biology, Universitas IndonesiaJakarta, Indonesia
Hariyanto, N.I., Master Program in BioMedical Sciences, Indonesian Medical Education and Research Institute (IMERI)Jakarta, Indonesia; Purwandhita, R.P., Master Program in BioMedical Sciences, Indonesian Medical Education and Research Institute (IMERI)Jakarta, Indonesia; Syahrani, R.A., Department of Molecular Biology and Proteomics, Indonesian Medical Education and Research Institute (IMERI)Jakarta, Indonesia; Louisa, M., Department of Pharmacology, Universitas IndonesiaJakarta, Indonesia; Wanandi, S.I., Department of BioChemistry and Molecular Biology, Universitas IndonesiaJakarta, Indonesia
OBJECTIVE: To investigate the auto-induction of transforming growth factor-b1 (TGF-β1) in breast cancer stem cells (BCSCs) and its effect on cell viability and stemness. Methods: Human BCSCs (aldehyde dehydrogenase positive; ALDH+) were grown in serum-free Dulbecco's Modified Eagle Medium/Nutrient Mixture F12 (DMEM/F12) and treated for periods of 1, 2 and 4 hours with 0.1 ng/ml recombinant human TGF-β1 protein (rhTGF-β1). The medium was then replaced with serum-free DMEM/F12 without rhTGF-β1 for 24 hours. Cell viability was determined using a trypan blue exclusion assay. Type 1 TGF-β receptor (TβR1), TGF-β1, octamer-binding transcription factor 4 (OCT4) and aldehyde dehydrogenase 1 family member A1 (ALDH1A1) messenger RNA (mRNA) expression levels were analysed using quantitative real-time reverse-transcriptase polymerase chain reaction (RT-qPCR). The TGF-β protein level in the culture medium was determined using an enzyme-linked immunosorbent assay (ELISA). RESULTS: The expression levels of rhTGF-β1, TGF-β1 and TβR1 mRNA significantly increased in BCSCs compared to control after treatment for 1 and 2 hours but decreased after 4 hours. This is in line with alteration of stemness gene, OCT4 and ALDH1A1 mRNA expressions. However, the secretion of newly synthesised TGF-β1 significantly increased after 2 hours. In contrast, viable BCSCs decreased after 1 hour and then gradually increased 2.7 times compared to control after 4 hours. CONCLUSIONS: TGF-β1 treatment in low concentration and for short period of time triggers its auto-induction in BCSCs, leading to increased cell viability and stemness gene expression via autocrine signalling.
Transforming Growth Factor beta1, Breast Neoplasms, Neoplastic Stem Cells, Octamer Transcription Factor-3, Aldehyde Dehydrogenase.
transforming growth factor; transforming growth factor beta; transforming growth factor beta1; breast tumor; cancer stem cell; human; Breast Neoplasms; Humans; Neoplastic Stem Cells; Transforming Growth Factor beta; Transforming Growth Factor beta1; Transforming Growth Factors
NLM (Medline)
309982
33785948
Article
Q3
245
16382